TScan Therapeutics, Inc. TCRX

Filed with the SEC on Sep 2, 2026. Reported event date Aug 27, 2026.

Items reported in this filing

Item 2.05 Costs Associated with Exit or Disposal Activities
The company reported a restructuring: it committed to exit or dispose of part of its business (for example closing some sites, ending a product line or cutting staff) and expects material costs, under Form 8-K Item 2.05. It does not mean the company is closing; healthy, profitable companies file it too, often alongside an earnings release.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
An exchange told the company it does not meet a continued-listing rule, or the company is delisting or moving its listing: Form 8-K Item 3.01. Many of these are compliance notices with time to fix, not closures.
Item 5.02 Departure or Appointment of Directors or Officers; Compensatory Arrangements
Item 7.01 Regulation FD Disclosure
Item 8.01 Other Events
Item 9.01 Financial Statements and Exhibits

Wire Pass $1.95/month or $19.50/year lets you watch up to 100 companies like this one. Free during preview See pricing